A short series of antidiabetic sulfonylureas exhibit multiple ligand PPARγ-binding patterns

Biomedicine and Pharmacotherapy

Volumn 63, Issue 1, 2009, Pages 56-62

  Arrault, Alban ^a   Rocchi, Stéphane ^b   Picard, Frédéric ^c   Maurois, Pierre ^d   Pirotte, Bernard ^e   Vamecq, Joseph ^b  

^a Université d'Orléans   (France)

^b INSERM   (France)

^c LAVAL UNIVERSITY   (Canada)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

2PRG structure; Docking; In silico studies; Ligand binding domain; Molecular interactions; PPAR ; Rosiglitazone; Selective PPAR modulation (SPPARM); Sulfonylureas

Indexed keywords

ANTIDIABETIC AGENT; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG STABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; LIGAND BINDING; MOLECULAR INTERACTION; PHYLOGENETIC TREE; PRIORITY JOURNAL;

ALGORITHMS; HYPOGLYCEMIC AGENTS; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PPAR GAMMA; PROTEIN BINDING; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONYLUREA COMPOUNDS;

EID: 58149083539     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.12.007     Document Type: Article

References (15)

1. Fukuen S., Iwaki M., Yasui A., Makishima M., and Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 280 (2005) 23653-23659
2. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8 (2001) 737-747
3. Maurois P., Rocchi S., Pages N., Bac P., Stables J.P., Gressens P., et al. The PPARγ agonist FMOC-l-leucine protects both mature and immature brain. Biomed Pharmacother 62 (2008) 259-263
4. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267 (1997) 727-748
5. http://www.rcsb.org/pdb/
6. http://www.chemcomp.com/
7. http://www.molecular-networks.com/
8. Halgren T.A. MMFF VI. MMFF94s option for energy minimization studies. J Comput Chem 20 (1999) 720-729
9. http://www.chemaxon.com/
10. Scarsi M., Podvinec M., Roth A., Hug H., Kersten S., Albrecht H., et al. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol 71 (2007) 398-406
11. Picard F., Gehin M., Annicotte J., Rocchi S., Champy M.F., O'Malley B.W., et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111 (2002) 931-941
12. Morosetti R., Servidei T., Mirabella M., Rutella S., Mangiola A., Maira G., et al. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol 25 (2004) 493-502
13. Perez-Ortiz J.M., Tranque P., Vaquero C.F., Domingo B., Molina F., Calvos S., et al. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279 (2004) 8976-8985
14. Renaud J., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., et al. Crystal structure of the RAR-[gamma] ligand-binding domain bound to all-trans retinoic acid. Nature 378 (1995) 681-689
15. Zoete V., Grosdidier A., and Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1171 (2007) 915-925